This website will be unavailable from Friday, April 26, 2024 at 6:00 p.m. through Monday, April 29, 2024 at 7:00 a.m. due to data center maintenance.

  84R8422 JSC-F
 
  By: Lozano, Wu, Guillen H.B. No. 1424
 
 
 
A BILL TO BE ENTITLED
 
AN ACT
  relating to the designation of certain synthetic compounds to
  Penalty Group 2 or 2-A of the Texas Controlled Substances Act;
  increasing penalties for certain persons convicted of the
  manufacture and delivery of controlled substances.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Sections 481.002(5) and (6), Health and Safety
  Code, are amended to read as follows:
               (5)  "Controlled substance" means a substance,
  including a drug, an adulterant, and a dilutant, listed in
  Schedules I through V or Penalty Group [Groups] 1, 1-A, [or] 2, 2-A,
  3, or [through] 4. The term includes the aggregate weight of any
  mixture, solution, or other substance containing a controlled
  substance.
               (6)  "Controlled substance analogue" means:
                     (A)  a substance with a chemical structure
  substantially similar to the chemical structure of a controlled
  substance in Schedule I or II or Penalty Group 1, 1-A, [or] 2, or
  2-A; or
                     (B)  a substance specifically designed to produce
  an effect substantially similar to, or greater than, the effect of a
  controlled substance in Schedule I or II or Penalty Group 1, 1-A,
  [or] 2, or 2-A.
         SECTION 2.  Section 481.103(a), Health and Safety Code, is
  amended to read as follows:
         (a)  Penalty Group 2 consists of:
               (1)  any quantity of the following hallucinogenic
  substances, their salts, isomers, and salts of isomers, unless
  specifically excepted, if the existence of these salts, isomers,
  and salts of isomers is possible within the specific chemical
  designation:
                     alpha-ethyltryptamine;
                     alpha-methyltryptamine;
                     5-(2-aminopropyl)benzofuran (5-APB);
                     6-(2-aminopropyl)benzofuran (6-APB);
                     5-(2-aminopropyl)-2,3-dihydrobenzofuran
  (5-APDB);
                     6-(2-aminopropyl)-2,3-dihydrobenzofuran
  (6-APDB);
                     5-(2-aminopropyl)indole (Trade or other names:
  5-IT, 5-API);
                     6-(2-aminopropyl)indole (Trade or other names:
  6-IT, 6-API);
                     Benzothiophenylcyclohexylpiperidine (BTCP);
                     4-bromo-2, 5-dimethoxyamphetamine (some trade or
  other names:  4-bromo-2, 5-dimethoxy-alpha-methylphenethylamine;
  4-bromo-2, 5-DMA);
                     4-bromo-2, 5-dimethoxyphenethylamine;
                     8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran-
  4-ethanamine (Trade or other name: Bromo-DragonFLY);
                     Bufotenine (some trade and other names:  3-(beta-
  Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)- 5-
  indolol; N, N-dimethylserotonin; 5-hydroxy-N, N-
  dimethyltryptamine; mappine);
                     Desoxypipradrol (2-benzhydrylpiperidine);
                     Diethyltryptamine (some trade and other names:  N,
  N-Diethyltryptamine, DET);
                     2, 5-dimethoxyamphetamine (some trade or other
  names:  2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA);
                     2, 5-dimethoxy-4-ethylamphetamine (trade or other
  name:  DOET);
                     2, 5-dimethoxy-4-(n)-propylthiophenethylamine
  (trade or other name:  2C-T-7);
                     Dimethyltryptamine (trade or other name:  DMT);
                     Diphenylprolinol (diphenyl(pyrrolidin-2-yl)
  methanol, D2PM);
                     Dronabinol (synthetic) in sesame oil and
  encapsulated in a soft gelatin capsule in a U.S. Food and Drug
  Administration approved drug product (some trade or other names for
  Dronabinol:  (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9-
  trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9-
  (trans)- tetrahydrocannabinol);
                     Ethylamine Analog of Phencyclidine (some trade or
  other names:  N-ethyl-1-phenylcyclohexylamine, (1-
  phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine,
  cyclohexamine, PCE);
                     2-ethylamino-2-(3-methoxyphenyl)cyclohexanone
  (Trade or other name: methoxetamine);
                     Ibogaine (some trade or other names:  7-Ethyl-6,
  6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-
  pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.);
                     5-iodo-2-aminoindane (5-IAI);
                     Mescaline;
                     5-methoxy-N, N-diisopropyltryptamine
  (5-MeO-DIPT);
                     5-methoxy-N, N-diallyltryptamine (5MeO-DALT);
                     5-methoxy-3, 4-methylenedioxy amphetamine;
                     4-methoxyamphetamine (some trade or other names:  
  4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine;
  PMA);
                     4-methoxymethamphetamine (PMMA);
                     2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone
  (Trade or other names: 2-MeO-ketamine; methoxyketamine);
                     1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP,
  PPMP);
                     4-methyl-2, 5-dimethoxyamphetamine (some trade
  and other names:  4-methyl-2, 5-dimethoxy-alpha-
  methylphenethylamine; "DOM"; "STP");
                     3,4-methylenedioxy methamphetamine (MDMA, MDM);
                     3,4-methylenedioxy amphetamine;
                     3,4-methylenedioxy N-ethylamphetamine (Also
  known as N-ethyl MDA);
                     5,6-methylenedioxy-2-aminoindane (MDAI);
                     Nabilone (Another name for nabilone:  (+)-trans-
  3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6,
  6-dimethyl-9H-dibenzo[b,d] pyran-9-one;
                     N-benzylpiperazine (some trade or other names:
  BZP; 1-benzylpiperazine);
                     N-ethyl-3-piperidyl benzilate;
                     N-hydroxy-3,4-methylenedioxyamphetamine (Also
  known as N-hydroxy MDA);
                     4-methylaminorex;
                     N-methyl-3-piperidyl benzilate;
                     O-Acetylpsilocin (Trade or other name:
  4-Aco-DMT);
                     Parahexyl (some trade or other names:  3-Hexyl-1-
  hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d]
  pyran; Synhexyl);
                     1-Phenylcyclohexylamine;
                     1-Piperidinocyclohexanecarbonitrile (PCC);
                     Psilocin;
                     Psilocybin;
                     Pyrrolidine Analog of Phencyclidine (some trade
  or other names:  1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);
                     Tetrahydrocannabinols, other than marihuana, and
  synthetic equivalents of the substances contained in the plant, or
  in the resinous extractives of Cannabis, or synthetic substances,
  derivatives, and their isomers with similar chemical structure and
  pharmacological activity such as:
                           delta-1 cis or trans tetrahydrocannabinol,
  and their optical isomers;
                           delta-6 cis or trans tetrahydrocannabinol,
  and their optical isomers;
                           delta-3, 4 cis or trans
  tetrahydrocannabinol, and its optical isomers;
                           compounds of these structures, regardless of
  numerical designation of atomic positions, since nomenclature of
  these substances is not internationally standardized;
                     Thiophene Analog of Phencyclidine (some trade or
  other names:  1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl
  Analog of Phencyclidine; TPCP, TCP);
                     1-pyrrolidine (some trade or other name:  TCPy);
                     1-(3-trifluoromethylphenyl)piperazine (trade or
  other name:  TFMPP); and
                     3,4,5-trimethoxy amphetamine;
               (2)  Phenylacetone (some trade or other names:  
  Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl
  ketone);
               (3)  unless specifically excepted or unless listed in
  another Penalty Group, a material, compound, mixture, or
  preparation that contains any quantity of the following substances
  having a potential for abuse associated with a depressant or
  stimulant effect on the central nervous system:
                     Aminorex (some trade or other names:  aminoxaphen;
  2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5-
  phenyl-2-oxazolamine);
                     Amphetamine, its salts, optical isomers, and
  salts of optical isomers;
                     Cathinone (some trade or other names:  2-amino-1-
  phenyl-1-propanone, alpha-aminopropiophenone, 2-
  aminopropiophenone);
                     Etaqualone and its salts;
                     Etorphine Hydrochloride;
                     Fenethylline and its salts;
                     Lisdexamfetamine, including its salts, isomers,
  and salts of isomers;
                     Mecloqualone and its salts;
                     Methaqualone and its salts;
                     Methcathinone (some trade or other names:  2-
  methylamino-propiophenone; alpha-(methylamino)propriophenone;
  2-(methylamino)-1-phenylpropan-1-one; alpha-N-
  methylaminopropriophenone; monomethylpropion; ephedrone, N-
  methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR
  1431);
                     N-Ethylamphetamine, its salts, optical isomers,
  and salts of optical isomers; and
                     N,N-dimethylamphetamine (some trade or other
  names:  N,N,alpha-trimethylbenzeneethaneamine;
  N,N,alpha-trimethylphenethylamine), its salts, optical isomers,
  and salts of optical isomers; and
               (4)  any compound structurally derived from
  2-aminopropanal by substitution at the 1-position with any
  monocyclic or fused-polycyclic ring system, including:
                     (A)  compounds further modified by:
                           (i)  substitution in the ring system to any
  extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl,
  hydroxyl, or halide substituents), whether or not further
  substituted in the ring system by other substituents;
                           (ii)  substitution at the 3-position with an
  acyclic alkyl substituent; or
                           (iii)  substitution at the 2-amino nitrogen
  atom with alkyl, [or] dialkyl, benzyl, or methoxybenzyl groups, or
  inclusion of the 2-amino nitrogen atom in a cyclic structure; and
                     (B)  by example, compounds such as:
                           4-Methoxymethcathinone (Also known as
  Methedrone);
                           4-Methylmethcathinone (Also known as
  Mephedrone);
                           3,4-Dimethylmethcathinone (Also known as
  3,4-DMMC);
                           3-Fluoromethcathinone (Also known as 3-FMC);
                           4-Fluoromethcathinone (Also known as
  Flephedrone);
                           3,4-Methylenedioxy-N-methylcathinone (Also
  known as Methylone);
                           3,4-Methylenedioxypyrovalerone (Also known
  as MDPV);
                           alpha-Pyrrolidinopentiophenone (Also known
  as alpha-PVP);
                           Naphthylpyrovalerone  (Also known as
  Naphyrone);
                           beta-Keto-N-methylbenzodioxolylpropylamine
  (Also known as Butylone);
                           beta-Keto-N-methylbenzodioxolylpentanamine
  (Also known as Pentylone);
                           beta-Keto-Ethylbenzodioxolylbutanamine
  (Also known as Eutylone); and
                           3,4-methylenedioxy-N-ethylcathinone (Also
  known as Ethylone).
         SECTION 3.  Section 481.1031, Health and Safety Code, is
  amended to read as follows:
         Sec. 481.1031.  PENALTY GROUP 2-A.  Penalty Group 2-A
  consists of any quantity of a synthetic chemical compound that is a
  cannabinoid receptor agonist and mimics the pharmacological effect
  of naturally occurring cannabinoids, including:
               naphthoylindoles structurally derived from
  3-(1-naphthoyl)indole with or without [by] substitution at the
  nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl,
  cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)
  methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl,
  (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl,
  or 2-(4-morpholinyl)ethyl, whether or not further substituted in
  the indole ring to any extent, whether or not substituted in the
  napthyl ring to any extent, including:
                     AM-2201;
                     JWH-004;
                     JWH-007;
                     JWH-009;
                     JWH-015;
                     JWH-016;
                     JWH-018;
                     JWH-019;
                     JWH-020;
                     JWH-046;
                     JWH-047;
                     JWH-048;
                     JWH-049;
                     JWH-050;
                     JWH-073;
                     JWH-076;
                     JWH-079;
                     JWH-080;
                     JWH-081;
                     JWH-082;
                     JWH-083;
                     JWH-093;
                     JWH-094;
                     JWH-095;
                     JWH-096;
                     JWH-097;
                     JWH-098;
                     JWH-099;
                     JWH-100;
                     JWH-116;
                     JWH-122;
                     JWH-148;
                     JWH-149;
                     JWH-153;
                     JWH-159;
                     JWH-164;
                     JWH-165;
                     JWH-166;
                     JWH-180;
                     JWH-181;
                     JWH-182;
                     JWH-189;
                     JWH-193;
                     JWH-198;
                     JWH-200;
                     JWH-210;
                     JWH-211;
                     JWH-212;
                     JWH-213;
                     JWH-234;
                     JWH-235;
                     JWH-239;
                     JWH-240;
                     JWH-241;
                     JWH-242;
                     JWH-258;
                     JWH-259;
                     JWH-260;
                     JWH-262;
                     JWH-267;
                     JWH-386;
                     JWH-387;
                     JWH-394;
                     JWH-395;
                     JWH-397;
                     JWH-398;
                     JWH-399;
                     JWH-400;
                     JWH-412;
                     JWH-413; and
                     JWH-414;
               naphthylmethylindones structurally derived from
  1H-indol-3-yl-(1-naphthyl)methane with or without [by]
  substitution at the nitrogen atom of the indole ring by alkyl,
  haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
  (N-methylpiperidin-2-yl)methyl, cyanoalkyl, (N-methylpyrrolidin-
  2-yl)methyl, (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-
  morpholinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not
  further substituted in the indole ring to any extent, whether or not
  substituted in the naphthyl ring to any extent, including:
                     JWH-175;
                     JWH-184;
                     JWH-185;
                     JWH-192;
                     JWH-194;
                     JWH-195;
                     JWH-196;
                     JWH-197; and
                     JWH-199;
               naphthoylpyrroles structurally derived from
  3-(1-naphthoyl)pyrrole with or without [by] substitution at the
  nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
  cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)
  methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl,
  (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl,
  or 2-(4-morpholinyl)ethyl, whether or not further substituted in
  the pyrrole ring to any extent, whether or not substituted in the
  naphthyl ring to any extent, including:
                     JWH-030;
                     JWH-145;
                     JWH-146;
                     JWH-147;
                     JWH-150;
                     JWH-156;
                     JWH-243;
                     JWH-244;
                     JWH-245;
                     JWH-246;
                     JWH-292;
                     JWH-293;
                     JWH-307;
                     JWH-308;
                     JWH-309;
                     JWH-346;
                     JWH-347;
                     JWH-348;
                     JWH-363;
                     JWH-364;
                     JWH-365;
                     JWH-366;
                     JWH-367;
                     JWH-368;
                     JWH-369;
                     JWH-370;
                     JWH-371;
                     JWH-372;
                     JWH-373; and
                     JWH-392;
               naphthylmethylindenes structurally derived from
  1-(1-naphthylmethyl)indene with or without [by] substitution at
  the 3-position of the indene ring by alkyl, haloalkyl, alkenyl,
  cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)
  methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl,
  (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl,
  or 2-(4-morpholinyl)ethyl, whether or not further substituted in
  the indene ring to any extent, whether or not substituted in the
  naphthyl ring to any extent, including:
                     JWH-171;
                     JWH-172;
                     JWH-173; and
                     JWH-176;
               phenylacetylindoles structurally derived from
  3-phenylacetylindole with or without [by] substitution at the
  nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl,
  cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)
  methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl,
  (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl,
  or 2-(4-morpholinyl)ethyl, whether or not further substituted in
  the indole ring to any extent, whether or not substituted in the
  phenyl ring to any extent, including:
                     AM-694;
                     AM-1241;
                     JWH-167;
                     JWH-203;
                     JWH-204;
                     JWH-205;
                     JWH-206;
                     JWH-208;
                     JWH-237;
                     JWH-248;
                     JWH-249;
                     JWH-250;
                     JWH-251;
                     JWH-252;
                     JWH-253;
                     JWH-302;
                     JWH-303;
                     JWH-305;
                     JWH-306;
                     JWH-311;
                     JWH-312;
                     JWH-313;
                     JWH-314; and
                     JWH-315;
               cyclohexylphenols structurally derived from
  2-(3-hydroxycyclohexyl)phenol with or without [by] substitution at
  the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl,
  cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)
  methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl,
  (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl,
  or 2-(4-morpholinyl)ethyl, whether or not substituted in the
  cyclohexyl ring to any extent, including:
                     CP-55,940;
                     CP-47,497;
                     analogues of CP-47,497, including VII, V, VIII, I,
  II, III, IV, IX, X, XI, XII, XIII, XV, and XVI;
                     JWH-337;
                     JWH-344;
                     JWH-345; and
                     JWH-405; [and]
               benzoylindoles structurally derived from
  3-(1-naphthoyl)indole with or without substitution at the nitrogen
  atom of the indole ring with alkyl, haloalkyl, alkenyl,
  cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)
  methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl,
  (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl,
  or 2-(4-morpholinyl)ethyl, whether or not further substituted in
  the indole ring to any extent, whether or not substituted in the
  phenyl ring to any extent, including:
                     1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4); and
                     1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
  methoxybenzoyl)indole (Pravadoline or WIN 48,098); and
               cannabinol derivatives, except where contained in
  marihuana, including tetrahydro derivatives of cannabinol and
  3-alkyl homologues of cannabinol or of its tetrahydro derivatives,
  such as:
                     Nabilone;
                     HU-210;
                     HU-211; and
                     WIN-55,212-2.
         SECTION 4.  Section 481.106, Health and Safety Code, is
  amended to read as follows:
         Sec. 481.106.  CLASSIFICATION OF CONTROLLED SUBSTANCE
  ANALOGUE. For the purposes of the prosecution of an offense under
  this subchapter involving the manufacture, delivery, or possession
  of a controlled substance, Penalty Groups 1, 1-A, [and] 2, and 2-A
  include a controlled substance analogue that:
               (1)  has a chemical structure substantially similar to
  the chemical structure of a controlled substance listed in the
  applicable penalty group; or
               (2)  is specifically designed to produce an effect
  substantially similar to, or greater than, a controlled substance
  listed in the applicable penalty group.
         SECTION 5.  Section 481.119(a), Health and Safety Code, is
  amended to read as follows:
         (a)  A person commits an offense if the person knowingly
  manufactures, delivers, or possesses with intent to deliver a
  controlled substance listed in a schedule by an action of the
  commissioner under this chapter but not listed in a penalty group.
  An offense under this subsection is a Class A misdemeanor, except
  that the offense is:
               (1)  a state jail felony, if the person has been
  previously convicted of an offense under this subsection; or
               (2)  a felony of the third degree, if the person has
  been previously convicted two or more times of an offense under this
  subsection.
         SECTION 6.  The changes in law made by this Act apply only to
  an offense committed on or after the effective date of this Act. An
  offense committed before the effective date of this Act is governed
  by the law in effect on the date the offense was committed, and the
  former law is continued in effect for that purpose. For purposes of
  this section, an offense was committed before the effective date of
  this Act if any element of the offense occurred before that date.
         SECTION 7.  This Act takes effect September 1, 2015.